Tabella med riassuntiva

Pagina 1

Cell source Cell type/s Advantages Criticalities Can be used? Autologous ___ isolated from patient and expanded Immune-compatible - Limited availability - Limited expandability - Invasive test - Risk of tumor (MSC) Y N (if cell patients are compromised) Autologous iPS from somatic cells of the patient and re- differentiated in ___ Immune-compatible - Risk of teratoma - Few protocols in re-differentation Y N (look at risk/benefit respect conventional therapy) Syngeneic Embryonic stem cells isolated from clones of the patient itself, and re-differentiated in ___ Immune-compatible (except for the mitochondrial DNA) - Risk of teratoma - Limitations of: ethical, technical and regulatory - Few protocols in re-differentation Y N (look at risk/benefit respect conventional therapy) Allogeneic (Stem cells/somatic cells) isolated from human donor and expanded - Available - Can be industrialized - Immunogenic - Risk of infection - Risk of tumor (MSC, multipotent cell) Y N (look at risk/benefit respect conventional therapy) Xenogeneic (Stem cells/somatic cells) isolated from non-human donor and expanded - Largely available from animal livestock - Can be industrialized - Acute immune rejection - Transmission of xeno-zoonoses - Limited biological functionality - Risk of tumor (MSC, multipotent cell) Y (if the patient is critical conditions and no other options) N